Amneal Pharmaceuticals

Q2 FY2026 EarningsQ2 FY26 results beat consensus across the top and bottom lines, with revenue of $796.2M (+3.28% vs. expected $770.9M) and normalized EPS of $0.18. Specialty segment revenue grew 16.6% YoY, driven by the strong launch of CREXONT®, while Affordable Medicines revenue rose 13% YoY due to new products. Operating leverage and lower interest expenses resulted in a significant net income beat, though GAAP results remain impacted by antitrust litigation and opioid settlement charges.